Construction of a Nomogram Model Based on the Pan-Immune-Inflammation Value for Prediction of Adverse Clinical Outcomes in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

基于泛免疫炎症值构建列线图模型,用于预测慢性阻塞性肺疾病急性加重期患者的不良临床结局

阅读:1

Abstract

PURPOSE: This study evaluated the predictive value of the pan-immune-inflammation value (PIV) and developed a nomogram that integrated the PIV to predict adverse clinical outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). PATIENTS AND METHODS: In a retrospective, single-center study, 522 patients with AECOPD were randomized 7:3 into the training and validation cohorts. Univariate and multivariate logistic regression were used to determine independent predictors of adverse clinical outcomes. After the optimal cutoff value for the PIV was determined, the training cohort was divided into the high-PIV and low-PIV groups. Receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA) were then performed to construct and validate the nomogram. RESULTS: The regression results identified age, serum albumin (ALB) level, partial pressure of carbon dioxide (PaCO(2)) level, and the PIV as independent predictors of adverse clinical outcomes, and they were included in the nomogram model. The AUCs of the nomogram model that included these four variables in the training and validation cohorts were 0.720 (95% confidence interval [CI]: 0.658-0.783) and 0.733 (95% CI: 0.626-0.840), respectively. The calibration curves of the two cohorts showed good prediction accuracy (Hosmer-Lemeshow test: both P > 0.05), and the DCA proved that the prediction model has some clinical value. CONCLUSION: Age, ALB level, PaCO(2) level, and the PIV are independent predictors of adverse clinical outcomes in patients with AECOPD and may help healthcare providers identify patients at high risk of adverse outcomes during early admission. Although promising, the nomogram model has only moderate predictive performance. Further studies are required to identify additional significant factors to develop a higher-performing prediction model with which to make more accurate decisions in clinical practice.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。